首页>投融资

Tubulis

B轮

Tubulis develops chemotherapeutic drugs to fight against cancer and chronic diseases. The company's chemotherapeutic drugs are uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology, enabling doctors to treat cancer patients without any side effects related to chemotherapy.In May 2022, Tubulis completed a €60 million Series B financing led by Andera Partners, Evotec and Fund+.In July 2020, the company announced closing of €10.7 million (US $12.4 million) series A financing round

https://tubulis.com/

470211

基本信息

公司全称

Tubulis GmbH
类型

药物偶联物研发商
产业领域

医药研发/制造、化学&生物药
公司人数

15人以下
地址

Butenandtstrasse 1 MUNICH BAYERN 81377; DE;
联系电话
邮箱

info@tubulis.com
成立时间

2019-01-01

投融资

2024-03-14

B轮

1.28亿欧元

Deep Track Capital

Frazier Management

EQT Partners

Nextech Invest
2024-03-14

B轮

1.28亿欧元

EQT Partners

Nextech Invest

Frazier Management

Deep Track Capital
2022-05-03

B轮

6000万欧元

High-TechGründerfonds

Seventure Partners

BioMedPartners

Occident Group

Fund+

Evotec

Bayern Kapital

coparion

Andera Partners
2022-05-03

B轮

6000万欧元

Bayern Kapital

Seventure Partners

Andera Partners

coparion

BioMedPartners

Occident Group

High-TechGründerfonds

Fund+

Evotec
2020-07-21

A轮

1070万欧元

High-TechGründerfonds

Seventure Partners

BioMedPartners

Occident Group

Bayern Kapital

coparion
2020-07-21

A轮

1070万欧元

Bayern Kapital

Seventure Partners

coparion

Occident Group

BioMedPartners

High-TechGründerfonds
2017-07-10

未公开

130万欧元

未透露
2017-07-10

未透露

130万欧元

未透露
加载更多

Tubulis

基本信息

投融资

相关投融资企业